207 related articles for article (PubMed ID: 30208863)
1. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER
BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863
[TBL] [Abstract][Full Text] [Related]
2. High frequency of BRAF V600E mutations in ameloblastoma.
Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
[TBL] [Abstract][Full Text] [Related]
3. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
[TBL] [Abstract][Full Text] [Related]
4. An immunohistochemical and genetic study of BRAF
Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T
Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640
[TBL] [Abstract][Full Text] [Related]
5. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
Yan XC; Sun LS; Dong ZW; You Z; Dong Q
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
[TBL] [Abstract][Full Text] [Related]
6. Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report.
Broudic-Guibert M; Blay JY; Vazquez L; Evrard A; Karanian M; Taïeb S; Hoog-Labouret N; Oukhatar CMA; Boustany-Grenier R; Arnaud A
J Med Case Rep; 2019 Jul; 13(1):245. PubMed ID: 31340860
[TBL] [Abstract][Full Text] [Related]
7. The Mutational Profile of Unicystic Ameloblastoma.
Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
[TBL] [Abstract][Full Text] [Related]
8. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
[TBL] [Abstract][Full Text] [Related]
9. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review.
You Z; Liu SP; Du J; Wu YH; Zhang SZ
J Oral Pathol Med; 2019 Mar; 48(3):201-205. PubMed ID: 30489659
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach.
Grynberg S; Vered M; Shapira-Frommer R; Asher N; Ben-Betzalel G; Stoff R; Steinberg Y; Amariglio N; Greenberg G; Barshack I; Toren A; Yahalom R; Schachter J; Rechavi G; Hirschhorn A; Abebe Campino G
J Natl Cancer Inst; 2024 Apr; 116(4):539-546. PubMed ID: 37966914
[TBL] [Abstract][Full Text] [Related]
11. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
[TBL] [Abstract][Full Text] [Related]
12. BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature.
Ebeling M; Scheurer M; Sakkas A; Pietzka S; Schramm A; Wilde F
Med Oncol; 2023 Apr; 40(6):163. PubMed ID: 37115331
[TBL] [Abstract][Full Text] [Related]
13. Progress towards personalized medicine for ameloblastoma.
Gomes CC; Diniz MG; Gomez RS
J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
[TBL] [Abstract][Full Text] [Related]
14. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.
Tan S; Pollack JR; Kaplan MJ; Colevas AD; West RB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jul; 122(1):e5-7. PubMed ID: 27209484
[TBL] [Abstract][Full Text] [Related]
15. Identification of recurrent SMO and BRAF mutations in ameloblastomas.
Sweeney RT; McClary AC; Myers BR; Biscocho J; Neahring L; Kwei KA; Qu K; Gong X; Ng T; Jones CD; Varma S; Odegaard JI; Sugiyama T; Koyota S; Rubin BP; Troxell ML; Pelham RJ; Zehnder JL; Beachy PA; Pollack JR; West RB
Nat Genet; 2014 Jul; 46(7):722-5. PubMed ID: 24859340
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for advanced ameloblastoma in the era of precision medicine: A brief review.
Oh KY
Oral Oncol; 2023 Nov; 146():106585. PubMed ID: 37816291
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
[TBL] [Abstract][Full Text] [Related]
18. Resolution of PTHrP-Mediated Hypercalcemia Following Treatment with Dual BRAF/MEK Inhibition for BRAFV600E-Positive Metastatic Ameloblastoma.
Corbett K; Ruether D; Seiden-Long I; Kline G
Calcif Tissue Int; 2024 Apr; 114(4):444-449. PubMed ID: 38252285
[TBL] [Abstract][Full Text] [Related]
19. Genetic Study of
Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K
Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576
[No Abstract] [Full Text] [Related]
20. Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review.
Yoithapprabhunath TR; Srichinthu KK; Gupta D; Singh D; Pasupuleti S; Nirmal RM
Indian J Dent Res; 2022; 33(3):323-331. PubMed ID: 36656197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
